Logo

Correction: Mar 11, 2005

Mar 11, 2005
Premium

RNAi News incorrectly reported last week that Cenix Bioscience has signed a deal with Schering expanding upon existing large-scale target screening projects. In fact,the arrangement is the companies’ first, and involves Cenix performing target validation for Schering, not target screening work.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.